Related Experiment Video
Updated: Aug 15, 2026

Photoacoustic Cystography
Published on: June 11, 2013
[New usage for an old drug: acetylcysteine for contrast-induced nephropathy]
Ilan Asher1, Ariel Hammerman, Zev Sthoeger
1Internal Medicine B Department, Kaplan Medical Center, Rehovot, Israel. ilan@kv-yavne.co.il
Insights
N-acetylcysteine may help prevent contrast-induced nephropathy, a common cause of hospital-acquired kidney injury. This antioxidant is recommended for high-risk patients due to its safety and low cost.
Area of Science:
- Nephrology
- Radiology
- Pharmacology
Background:
- Contrast-induced nephropathy (CIN) is a significant cause of hospital-acquired renal failure.
- Pathophysiology involves direct renal toxicity and medullary ischemia, with hydration being partially effective.
- Existing preventive measures for CIN have limitations.
Purpose of the Study:
- To evaluate the efficacy of N-acetylcysteine in preventing contrast-induced nephropathy.
- To assess the role of N-acetylcysteine in patients with moderate renal insufficiency undergoing contrast procedures.
Main Methods:
- Review of several prospective, randomized, placebo-controlled studies.
- Analysis of N-acetylcysteine's safety profile and cost-effectiveness.
- Focus on patient populations with moderate renal insufficiency.
Main Results:
- N-acetylcysteine appears to reduce the risk of contrast-induced nephropathy.
- Some discrepancies in results exist across studies.
- N-acetylcysteine demonstrates a favorable safety profile and low cost.
Conclusions:
- N-acetylcysteine is recommended for preventing contrast-induced nephropathy in high-risk patients.
- Further research may clarify optimal usage and efficacy.
- The antioxidant offers a potentially valuable addition to CIN prevention strategies.
Abstract:
Contrast induced nephropathy is the third common cause of hospital-acquired renal failure. The pathophysiology and the mechanism involved in the contrast media induced renal failure are not well understood but it is thought to be the result of direct renal toxicity and medullary ischemia. The only preventive measure proven to reduce such nephropathy is hydration (pre- and post-procedure). However, the above treatment is partially effective. The antioxidant N-acetylcysteine has recently been studied for the prevention of contrast induced nephropathy in several prospective, randomized, placebo-controlled studies among patients with moderate renal insufficiency. Although some discrepancies exist, N-acetylcysteine appears to reduce the risk of contrast-induced nephropathy. N-acetylcysteine has a safety profile and low cost. Taken together, N-acetylcysteine is recommended for the prevention of contrast-induced nephropathy in high-risk patients.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Imaging Studies III: Computed Tomography
Acute Kidney Injury V: Interprofessional Care
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Radiological Investigation I: X-ray and CT
Imaging Studies VII: Vascular Imaging
